Should checkpoint inhibitors be reserved for biomarker-selected pediatric brain tumors?
Yaxel Levin-Carrion, Jayant Bhasin, Kevin Titkov, Sraavya Anne, Arman Sawhney, Caryn J. Ha, Ibraheem Sharaf, Marvens Jean, Jacob Santana, Drew Thibault, Alejandro Pando, Nemanja Novakovic, Nehal S. Parikh, Morana Vojnic, Jonathan H. Sherman · 2026
Read Should checkpoint inhibitors be reserved for biomarker-selected pediatric brain tumors? by Yaxel Levin-Carrion, Jayant Bhasin, Kevin Titkov, Sraavya Anne, Arman Sawhney, Caryn J. Ha, Ibraheem Sharaf, Marvens Jean, Jacob Santana, Drew Thibault, Alejandro Pando, Nemanja Novakovic, Nehal S. Parikh, Morana Vojnic, Jonathan H. Sherman (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13179885.txt.
Description
Levin-Carrion and a large team ask if immune drugs for brain tumors in youth should be saved for picked cases, in a review from twenty twenty-six. These tumors are a top cause of death in youth. Most are cold, with few immune cells inside and few gene changes. Cold tumors tend to shrug off drugs that free the immune system to attack.
The team screened hundreds of reports and kept forty for close review. In unpicked groups, the drugs helped very few patients and for a short time. Harm was in a range doctors can manage. In youth with faulty gene repair and many mutations, the drugs helped far more. Some saw full clearing that lasted. The team urges trials that pick patients by gene marks.
Catalog record
| CREATOR | Yaxel Levin-Carrion, Jayant Bhasin, Kevin Titkov, Sraavya Anne, Arman Sawhney, Caryn J. Ha, Ibraheem Sharaf, Marvens Jean, Jacob Santana, Drew Thibault, Alejandro Pando, Nemanja Novakovic, Nehal S. Parikh, Morana Vojnic, Jonathan H. Sherman |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |